HURA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TuHURA Biosciences Inc (HURA) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has potential catalysts such as its upcoming Phase 2 clinical trial and a favorable safety profile for its drug candidate, the financial performance is weak, with no revenue and negative EPS. Additionally, the technical indicators and trading signals do not suggest a compelling entry point currently. It is better to monitor the stock for further developments, especially after the upcoming earnings report on February 26, 2026.
The MACD histogram is positive at 0.0672 but contracting, indicating weakening momentum. RSI is neutral at 57.982, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. Key support and resistance levels are at 1.009 (pivot), 1.44 (R1), and 0.579 (S1). Overall, the technical indicators do not signal a strong buy opportunity.
TuHURA Biosciences has filed an Investigational New Drug application with the FDA for TBS-
The company plans to start a Phase 2 clinical trial in early Q2 2026, with preliminary results expected in Q3
TBS-2025 has shown a favorable safety profile in early trials, which could improve treatment responses for mutNPM1 mutations.
The company has no revenue and negative EPS (-0.14), indicating poor financial health.
The stock has experienced consistent price declines (-2.22% pre-market, -1.33% regular market, -0.77% post-market).
Analysts have lowered the price target from $12 to $10, reflecting reduced optimism.
In Q3 2025, the company reported no revenue (0% YoY growth). Net income improved to -$7,104,544 (up 252.93% YoY), but EPS dropped significantly to -0.14 (-99.71% YoY). Gross margin remains at 0%. Overall, the financials indicate a lack of profitability and growth.
H.C. Wainwright analyst Robert Burns maintains a Buy rating but has lowered the price target from $12 to $10, citing the recent stock decline as an attractive entry point. However, this optimism is tempered by the company's weak financials and lack of revenue.
